Soonmyung Paik

Research interests

Publications

• Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1904819

• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1804710

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourina

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000161

• Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000162

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000161

• Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv161

• Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1510764

• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(13)62422-8

• Nanomaterials for Theranostics: Recent Advances and Future Challenges

  Chemical Reviews · 2014 · 10.1021/cr300213b

• Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2013.50.9984

• Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.23.7610

• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)

  Archives of Pathology & Laboratory Medicine · 2010 · https://doi.org/10.5858/134.7.e48

• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.25.6529

• Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.15.0235

• Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.15.1068

• Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2005.04.7985

• HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations

  Journal of the National Comprehensive Cancer Network · 2006 · https://doi.org/10.6004/jnccn.2006.2003

• Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2005.04.1665

• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

  Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2006.09.2775

• Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa052122

• A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa041588

• Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.11.101

• erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 1998 · 10.1093/jnci/90.18.1361

• Pathologic findings from the national surgical adjuvant breast project (protocol 6) I. Intraductal carcinoma (DCIS)

  Cancer · 1986 · 10.1002/1097-0142(19860115)57:2<197::aid-cncr2820570203>3.0.co;2-n

Current projects

No projects listed.